August 2012
-
The 2012 annual meeting of the American Association of Pharmaceutical Scientists, which took place from October 14-18 at the McCormick Place convention center in Chicago, drew a number of inhalation and nasal specialists for the… Read more . . .
-
On October 17, MannKind Corporation announced a plan to sell 40,000,000 shares of its common stock, plus warrants to purchase up to 30,000,000 shares, in a public offering, which it said may or may not… Read more . . .
-
Market research firm Frost & Sullivan is presenting its 2012 Global Enabling Technology Award to Alexza Pharmaceuticals for its Staccato thermal vaporization inhaler platform. The award is designed to recognize a company for “developing a… Read more . . .
-
Contract manufacturer PharmaForm, a subsidiary of Akela Pharma, has announced plans to move from Austin, TX to the San Diego, CA area. The company offers formulation and manufacturing services for numerous dosage forms, including nasal… Read more . . .
-
MAP Pharmaceuticals has resubmitted its New Drug Application (NDA) for Levadex inhaled dihydroergotamine for the treatment of migraine to the FDA, the company has announced. The FDA issued a complete response letter to MAP in… Read more . . .
-
According to Chiesi Group, a Phase 1 trial of its inhaled phosphodiesterase 4 (PDE4) inhibitor for the treatment of lung diseases such as COPD and asthma demonstrated that the drug, known as CHF 6001, was… Read more . . .
-
The United States’ National Aeronautics and Space Administration (NASA) has signed a development and commercialization agreement with Epiomed Therapeutics for intranasal scopolamine. The nasal spray for the treatment of motion sickness is also called INSCOP.… Read more . . .
-
Almirall has announced that Invida Holdings has licensed the rights to market aclidinium bromide inhalers for the treatment of COPD in Australia and New Zealand. The deal covers Genuair DPIs with aclidinium alone and a… Read more . . .
-
NanoBio Corporation, which is developing a several intranasal vaccines, has announced that David Peralta will succeed James R. Baker as the company’s Chief Executive Officer after Baker was hired by Merck as Senior VP, Head… Read more . . .
-
Powder characterization specialist Freeman Technology has reached an agreement with distribution partner DKSH to expand into China. DKSH already distributes Freeman’s FT4 Powder Rheometer in Singapore, Malaysia, Thailand and Taiwan and will now distribute the… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland